

Die besten Biotechs der Schweiz

Für das Life Sciences Special hat Patrik Frei von Venture Valuation die Pipelines der Biotech-Startups analysiert. Phase III Wirkstoffe haben Actelion (4), Basilea (1) und Preglem (1).

Firma	Wirkstoffe
Kuros Biosurgery AG (private)	14
Actelion Pharmaceuticals Ltd. (public)	13
mondoBIOTECH AG (public)	11
Cytos Biotechnology AG (public)	10
Synosia Therapeutics AG (private)	9
Kenta Biotech Ltd. (private)	8
Santhera (public)	8
AC IMMUNE SA (private)	6
Basilea Pharmaceutica Ltd. (public)	6
Evolva Holding SA (public)	6
NovImmune (private)	6
Pevion Biotech Ltd. (private)	6
Addex Pharmaceuticals (public)	5
Lumavita AG (private)	4
PregLem SA (private)	4
Polyphor Ltd (private)	3
AURIS MEDICAL AG (private)	2

Quelle: biogate.com